Cellectis researchers have published a proof-of-concept study detailing the activity of “smart” T-cells capable of sensing and reacting to tumors by secreting therapeutic proteins that improve their ability to fight cancerous cells, potentially paving the way for a next generation of tightly-controlled, highly active—and potentially safer—CAR T-cell treatments. By using gene editing to rewire the TCRα, CD25 and PD1 genes along the TCR activation pathway, CAR T-cells were able to reshape the tumor microenvironment by micro secreting the pro-inflammatory cytokine Interleukin 12 (IL-12) in a tumor- and time-dependent manner.
The recent epigenetic drug discovery and development attention and investment is driven by the potential to develop novel therapeutic strategies that can effectively reverse transcriptional and epigenetic abnormalities that are present in many human disorders.
Collaboration will focus on infections including dengue fever, chikungunya and hand, foot and mouth disease.
Twenty-six years after it began development, Sanofi’s dengue prevention vaccine Dengvaxia® (Dengue Tetravalent Vaccine, Live) has won FDA approval—albeit in a narrower patient population...
Scientists exploit ZouA to amplify gene cluster between replication sites.
Korean Institute will use PhenomicScreen to mine partners’ compound libraries.
Toxicity screening specialist CeeTox and stem cell technologies firm Cellular Dynamics have teamed up to devise and offer an in vitro predictive cardiac safety screening services using human induced pluripotent stem cell (iPSC)-derived cardiomyocytes.
Studies in mice by an international team of scientists suggest that inhibiting a single gene could combat obesity and related metabolic disorders by allowing...
Please wait while you are redirected to the right page...